Announcements Trials
Browse Landscape

Status

Available 2No longer available 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 479Observational 84Expanded_access 3

Sponsor

Cancer Type

Dermatologic 21Gastrointestinal 4Thoracic 3Gynecologic 3Genitourinary 3CNS 3Sarcoma 1Head & Neck 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 34Lung Neoplasms 9Small Cell Lung Carcinoma 8Pancreatic Neoplasms 7Prostatic Neoplasms 5Ovarian Neoplasms 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Breast Neoplasms 4Sarcoma 3Melanoma 3Carcinoma, Renal Cell 3Carcinoma 3Thyroid Neoplasms 2Neoplasms 2Chondrosarcoma 2Cholangiocarcinoma 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2Adenocarcinoma of Lung 2Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous Non-Small Cell Lung Cancer 1Sarcoma, Synovial 1Rhabdoid Tumor 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1

Interventions

ulixertinib 1pegilodecakin 1balstilimab 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Expanded_access × Melanoma × Thoracic × Clear all
NCT06751524 2026-05-15

Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval

Agenus Inc.

Available
DermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT04566393 2026-01-28

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies

xCures

Available
CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT03554434 2020-03-02

An Expanded Access Program for AM0010 (Pegilodecakin)

Eli Lilly and Company

No longer available
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡